retatrutide ly3437943 parkinson's disease clinical trial of Lixisenatide in Early A Study of Retatrutide (LY3437943)

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly for obesity and metabolic conditions

This means that a 250-pound individual could expect to lose around 37 pounds, on average

Research consistently shows that losing more than 1-2 pounds weekly significantly increases hair loss risk

Retatrutide dosing schedule The retatrutide dosing protocol from clinical trials follows a similar but slightly different titration pattern: Week 1-4: 1-2 mg once weekly (starting dose varies by protocol) Week 5-8: 4 mg once weekly Week 9-12: 8 mg once weekly Week 13+: 12 mg once weekly (maximum dose) The dose increases are larger and less granular than Mounjaro

Vitamin B12 helps your bodys cells produce the energy they need to function and helps reduce fatigue for those low in B12, which may include adults who limit animal-based foods